- type IV hypersensitivity
- act later than planned, scheduled, or required; "Dont delay your application to graduate school or else it wont be considered"
- time during which some action is awaited; "instant replay caused too long a delay"; "he ordered a hold in the action" (同)hold, time_lag, postponement, wait
- the act of delaying; inactivity resulting in something being put off until a later time (同)holdup
- cause to be slowed down or delayed; "Traffic was delayed by the bad weather"; "she delayed the work that she didnt want to perform" (同)detain, hold_up
- not as far along as normal in development
- pathological sensitivity
- extreme sensitivity
- …'を'『延期する』,延ばす / 〈事故などが〉…'を'『遅らせる』 / 『ぐずぐずする』,『手間取る』 / 『遅れ』,遅延 / 『延期』,猶予
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- Coronary drug-eluting stents: From design optimization to newer strategies.
- Sun D1, Zheng Y, Yin T, Tang C, Yu Q, Wang G.Author information 1Key Laboratory of Biorheological Science and Technology (Chongqing University), Ministry of Education, Chongqing Engineering Laboratory in Vascular Implants, Bioengineering College of Chongqing University, Chongqing, 400044, People's Republic of China.AbstractCompared with early bare-metal stents, drug-eluting stents (DESs) are more effective in treating coronary artery diseases, especially in inhibiting restenosis. However, in-stent restenosis still clinically occurs at a non-negligible rate. More importantly, delayed endothelialization, inflammation, and hypersensitivity trigger subacute or late adverse events, particularly stent thrombosis, and thereby raise more concerns over the long-term safety of DESs. These problems are mostly associated with the permanent polymeric materials, non-optimal therapeutic drugs, and/or metallic stent platforms used in current DES design. It is critically important to further improve and optimize DES design and apply newer strategies for developing next generation DES. These new generation DESs should maintain their clinical efficacy and meanwhile eliminate the long-term safety concerns. In this review article, the current information on the optimization of DES design was critically reviewed based on DES's basic components, namely, stent platform, restenotic drug, and polymer coating. The available strategies for designing next-generation DESs were also summarized, ranging from degradable polymer DESs, to polymer-free DESs, to fully biodegradable DESs. © 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 102A: 1625-1640, 2014.
- Journal of biomedical materials research. Part A.J Biomed Mater Res A.2014 May;102(5):1625-40. doi: 10.1002/jbm.a.34806. Epub 2013 Jul 1.
- Compared with early bare-metal stents, drug-eluting stents (DESs) are more effective in treating coronary artery diseases, especially in inhibiting restenosis. However, in-stent restenosis still clinically occurs at a non-negligible rate. More importantly, delayed endothelialization, inflammation, a
- PMID 23703913
- Evaluation of the relation between patient characteristics and the state of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving paclitaxel and carboplatin.
- Furukawa N1, Akasaka J, Shigemitsu A, Sasaki Y, Nagai A, Kawaguchi R, Kobayashi H.Author information 1Department of Obstetrics and Gynecology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan, firstname.lastname@example.org.AbstractPURPOSE: An antiemetic regimen for patients taking paclitaxel and carboplatin (TC) includes dexamethasone (20 mg) to protect against hypersensitivity. Chemotherapy-induced nausea and vomiting (CINV), however, is difficult to adequately control in patients receiving TC. In the present study, we retrospectively investigated risk factors for CINV in patients receiving TC with this antiemetic regimen based on a questionnaire.
- Archives of gynecology and obstetrics.Arch Gynecol Obstet.2014 Apr;289(4):859-64. doi: 10.1007/s00404-013-3058-7. Epub 2013 Nov 2.
- PURPOSE: An antiemetic regimen for patients taking paclitaxel and carboplatin (TC) includes dexamethasone (20 mg) to protect against hypersensitivity. Chemotherapy-induced nausea and vomiting (CINV), however, is difficult to adequately control in patients receiving TC. In the present study, we retr
- PMID 24185939
- Reactive metabolites as a cause of late diabetic complications.
- Fleming T, Nawroth PP.Author information *Department of Medicine I and Clinical Chemistry, University Hospital of Heidelberg, INF 410, 69120 Heidelberg, Germany.AbstractPatients suffering from DN (diabetic neuropathy) suffer from the coexistence of positive (i.e. pain, hypersensitivity, tingling, cramps, cold feet, etc.) and negative (i.e. loss of sensory perception, delayed wound healing, etc.) symptoms. Elevated blood glucose alone cannot explain the development and progression of DN. Recently it has been shown that the endogenous reactive metabolite MG (methylglyoxal), elevated as a consequence of reduced Glo1 (glyoxalase I), can contribute to the gain of function via post-translational modification of neuronal ion channels involved in chemosensing and action potential generation in nociceptive nerve endings. The effects of dicarbonyls on the neuronal compartment provides a unifying mechanism for the development of DN. Targeting the accumulation and effects of MG may therefore provide new, more effective, therapeutic approaches for the treatment of DN.
- Biochemical Society transactions.Biochem Soc Trans.2014 Apr 1;42(2):439-42. doi: 10.1042/BST20130265.
- Patients suffering from DN (diabetic neuropathy) suffer from the coexistence of positive (i.e. pain, hypersensitivity, tingling, cramps, cold feet, etc.) and negative (i.e. loss of sensory perception, delayed wound healing, etc.) symptoms. Elevated blood glucose alone cannot explain the development
- PMID 24646257
- Development of a Delayed-Type Hypersensitivity (DTH) Model in the Cynomolgus Monkey
- Bouchez Caroline,Gervais Frederic,Fleurance Renaud [他]
- Journal of toxicologic pathology 25(2), 183-188, 2012
- NAID 40019378849
- サトウキビ抽出物の飼料添加が子豚の免疫機能に及ぼす影響 (日本獣医師会学会学術誌) -- (産業動物臨床・家畜衛生関連部門)
- 4 May 2011 ... Delayed hypersensitivity reactions are inflammatory reactions initiated by mononuclear leukocytes. The term delayed is used to differentiate a secondary cellular response, which appears 48-72 hours after antigen exposure, ...
- Type IV hypersensitivity is often called delayed type hypersensitivity as the reaction takes two to three days to develop. Unlike the other types, it is not antibody mediated but rather is a type of cell-mediated response. CD4+ helper T cells ...